Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Friberg

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Journal of Medicinal Chemistry|February 16, 2016
Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based MethodsNicholas F Pelz, Zhiguo Bian, Bin Zhao, et al.
Leukemia|April 4, 2019
The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignanciesSven Christian, Claudia Merz, Laura Evans, et al.
Journal of Medicinal Chemistry|October 21, 2022
Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists <b>BAY-4931</b> and <b>BAY-0069</b>Douglas L Orsi, Elisabeth Pook, Nico Bräuer, et al.
Journal of Medicinal Chemistry|December 21, 2022
Correction to "Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069"Douglas L Orsi, Elisabeth Pook, Nico Bräuer, et al.
Bioorganic & Medicinal Chemistry|December 21, 2022
Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonistsDouglas L Orsi, Steven J Ferrara, Stephan Siegel, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Journal of Medicinal Chemistry|February 16, 2016
Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based MethodsNicholas F Pelz, Zhiguo Bian, Bin Zhao, et al.
Leukemia|April 4, 2019
The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignanciesSven Christian, Claudia Merz, Laura Evans, et al.
Journal of Medicinal Chemistry|October 21, 2022
Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists <b>BAY-4931</b> and <b>BAY-0069</b>Douglas L Orsi, Elisabeth Pook, Nico Bräuer, et al.
Journal of Medicinal Chemistry|December 21, 2022
Correction to "Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069"Douglas L Orsi, Elisabeth Pook, Nico Bräuer, et al.
Bioorganic & Medicinal Chemistry|December 21, 2022
Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonistsDouglas L Orsi, Steven J Ferrara, Stephan Siegel, et al.
Pageof 5